Subscribe for the newsletter
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Alkermes
Sort By
Newest First
Sign in
1 / 1
1 / 1
Leadership
Alkermes Announces the Appointment of Board of Directors
Alkermes
PA2111
Sep 18, 2019
Research
Alkermes Launches Award Program To Support And Advance Central Nervous System Disorders Research
Alkermes
PR-M05-18-NI-033
May 09, 2018
Clinical Trials
Alkermes Completes Patient Enrollment in Pivotal Weight Study of ALKS 3831 for Schizophrenia
Alkermes
PR-M05-18-NI-007
May 02, 2018
Innovation
Study Reveals New Medication Options for Opioid Dependency
Nice Insight
PAO-M11-17-NI-040
Nov 23, 2017
Innovation
Patients Switched to Alkermes’ ARISTADA® Showed Significant Improvement in Schizophrenia Symptoms After Inadequate Response or Intolerance to INVEGA SUSTENNA®
Alkermes
PR-M09-17-NI-005
Sep 20, 2017
